Sugentech Inc
Sugentech Inc. develops and sells in-vitro diagnostic systems and products based on biotechnology, information technology, and nanotechnology in South Korea and internationally. The company offers lab tests, including systems and test items; and COVID-19 tests. It also provides point of care testing analyzers and test items for testing of influenza A/B, antibody test, COVID-19 and flu, SARS-CoV-2… Read more
Sugentech Inc (253840) - Net Assets
Latest net assets as of September 2025: ₩87.93 Billion KRW
Based on the latest financial reports, Sugentech Inc (253840) has net assets worth ₩87.93 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩108.61 Billion) and total liabilities (₩20.68 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩87.93 Billion |
| % of Total Assets | 80.96% |
| Annual Growth Rate | N/A |
| 5-Year Change | 53.91% |
| 10-Year Change | N/A |
| Growth Volatility | 59.4 |
Sugentech Inc - Net Assets Trend (2017–2024)
This chart illustrates how Sugentech Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Sugentech Inc (2017–2024)
The table below shows the annual net assets of Sugentech Inc from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩97.13 Billion | -13.63% |
| 2023-12-31 | ₩112.45 Billion | -20.00% |
| 2022-12-31 | ₩140.58 Billion | +39.59% |
| 2021-12-31 | ₩100.71 Billion | +59.59% |
| 2020-12-31 | ₩63.11 Billion | +159.63% |
| 2019-12-31 | ₩24.31 Billion | +57.26% |
| 2018-12-31 | ₩15.46 Billion | +147.11% |
| 2017-12-31 | ₩-32.81 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Sugentech Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 7037285584000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩32.33 Billion | 33.29% |
| Common Stock | ₩8.37 Billion | 8.62% |
| Other Components | ₩56.42 Billion | 58.09% |
| Total Equity | ₩97.13 Billion | 100.00% |
Sugentech Inc Competitors by Market Cap
The table below lists competitors of Sugentech Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Yulon Nissan Motor Co Ltd
TW:2227
|
$44.73 Million |
|
Holiday Entertainment Co Ltd
TW:9943
|
$44.75 Million |
|
Guerbet SA
F:4G8
|
$44.77 Million |
|
Ratchaphruek Hospital Public Company Limited
BK:RPH
|
$44.77 Million |
|
Lingotes
MC:LGT
|
$44.72 Million |
|
RediShred Capital Corp
PINK:RDCPF
|
$44.72 Million |
|
NACL Industries Limited
NSE:NACLIND
|
$44.71 Million |
|
Airgain Inc
NASDAQ:AIRG
|
$44.70 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sugentech Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 112,394,840,350 to 97,126,326,500, a change of -15,268,513,850 (-13.6%).
- Net loss of 15,192,705,140 reduced equity.
- Share repurchases of 17,175,000 reduced equity.
- New share issuances of 17,175,000 increased equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-15.19 Billion | -15.64% |
| Share Repurchases | ₩17.18 Million | -0.02% |
| Share Issuances | ₩17.18 Million | +0.02% |
| Other Changes | ₩-75.81 Million | -0.08% |
| Total Change | ₩- | -13.58% |
Book Value vs Market Value Analysis
This analysis compares Sugentech Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.80x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩-6699.09 | ₩5090.00 | x |
| 2018-12-31 | ₩1352.73 | ₩5090.00 | x |
| 2019-12-31 | ₩1880.41 | ₩5090.00 | x |
| 2020-12-31 | ₩4125.87 | ₩5090.00 | x |
| 2021-12-31 | ₩6216.91 | ₩5090.00 | x |
| 2022-12-31 | ₩8640.89 | ₩5090.00 | x |
| 2023-12-31 | ₩7481.63 | ₩5090.00 | x |
| 2024-12-31 | ₩6352.41 | ₩5090.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sugentech Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -15.64%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -150.47%
- • Asset Turnover: 0.09x
- • Equity Multiplier: 1.11x
- Recent ROE (-15.64%) is above the historical average (-43.14%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | -609.32% | 0.19x | 0.00x | ₩-17.68 Billion |
| 2018 | -264.72% | -750.91% | 0.22x | 1.58x | ₩-42.46 Billion |
| 2019 | -39.34% | -248.66% | 0.08x | 1.87x | ₩-11.99 Billion |
| 2020 | -65.00% | -99.19% | 0.57x | 1.15x | ₩-47.33 Billion |
| 2021 | 35.90% | 46.83% | 0.50x | 1.54x | ₩26.08 Billion |
| 2022 | 19.00% | 26.35% | 0.59x | 1.23x | ₩12.66 Billion |
| 2023 | -15.34% | -241.69% | 0.05x | 1.18x | ₩-28.48 Billion |
| 2024 | -15.64% | -150.47% | 0.09x | 1.11x | ₩-24.91 Billion |
Industry Comparison
This section compares Sugentech Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $98,321,642,752
- Average return on equity (ROE) among peers: 7.10%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sugentech Inc (253840) | ₩87.93 Billion | 0.00% | 0.24x | $44.73 Million |
| Shinhung (004080) | $87.31 Billion | 3.50% | 0.52x | $10.80 Million |
| Osang Healthcare Co.,Ltd (036220) | $199.86 Billion | 20.34% | 0.25x | $37.44 Million |
| HansBiomed Corporation (042520) | $43.16 Billion | 11.38% | 0.21x | $246.58 Million |
| JVM Co. Ltd (054950) | $98.83 Billion | 10.23% | 0.72x | $117.37 Million |
| Huvitz Co. Ltd (065510) | $51.68 Billion | 16.97% | 0.32x | $43.64 Million |
| Vieworks Co. Ltd (100120) | $188.04 Billion | 17.80% | 0.28x | $101.54 Million |
| Corentec Co Ltd (104540) | $48.30 Billion | -3.04% | 0.46x | $40.80 Million |
| Hironic Co. Ltd (149980) | $40.72 Billion | 7.13% | 0.15x | $23.71 Million |
| Laseroptek Co., Ltd. (199550) | $-3.94 Billion | 0.00% | 0.00x | $21.68 Million |
| Humasis Co. Ltd (205470) | $229.26 Billion | -13.28% | 0.45x | $48.97 Million |